Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Kymriah wins second FDA OK, boosting hope for Novartis' low CAR-T sales
8 years ago
R&D
Pharma
‘Biohacker’ Traywick dead at 28 — known for self-injecting a DIY herpes drug
8 years ago
People
Pfizer cuts five cancer programs; George Church engages Cellectis' TALEN tech to create virus-resistant human cells
8 years ago
News Briefing
Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics
8 years ago
R&D
Pharma
Under pressure, Peter Hecht splits Ironwood into two biotechs, spinning out an R&D operation
8 years ago
R&D
Biogen tosses in an extra $50M for a bigger slice of the royalties for its PhIII Alzheimer’s drug aducanumab
8 years ago
Pharma
Sanofi/Regeneron’s one-two punch on PCSK9 price and health data wins a key convert as Express Scripts creates ...
8 years ago
Pharma
Omega Funds leads $35M Series A to fuel Attenua's cough program, set for proof-of-concept this year
8 years ago
Financing
Startups
Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology
8 years ago
R&D
Pharma
IDO rout: Pivotal trials with Bristol-Myers, Merck and AstraZeneca dumped in wake of Incyte's PhIII implosion
8 years ago
R&D
Karyopharm stock soars on selinexor's positive PhIIb update, plans for an NDA
8 years ago
R&D
Eyeing Eylea's $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
8 years ago
R&D
Two biotechs hunt $175 million in Nasdaq pursuit; Keryx CEO Gregory Madison abruptly resigns; RxCelerate buys ...
8 years ago
News Briefing
Allergan's $639M Vitae buyout is a bust. R&D writes off their psoriasis program as a complete loss
8 years ago
R&D
Spark's PRV draws lukewarm price, selling for $110M to Jazz
8 years ago
Pharma
Leena Gandhi steps out of Keytruda spotlight and into a top research job at I/O laggard Eli Lilly
8 years ago
People
IL-2 without the toxic side effects? Orbimed backs the idea in Synthorx' $63M round
8 years ago
Financing
Startups
Who’s the top earning CEO in biopharma? Martine Rothblatt once again hits top slot with $37M pay package
8 years ago
People
United Therapeutics bags rival SteadyMed for a bargain basement deal worth up to $216M, eliminating patent threat
8 years ago
Deals
What do you get when you integrate healthcare data from multiple sources into one comprehensive, global package? ...
8 years ago
Financing
Deals
Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 ...
8 years ago
Pharma
Crescendo snares $70M Series B for its tumor-fighting tech
8 years ago
Financing
Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study
8 years ago
Financing
Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant
8 years ago
R&D
First page
Previous page
1031
1032
1033
1034
1035
1036
1037
Next page
Last page
